News

• 20/09/2022

  ARECOR PRESENTS DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 AT EASD

  ↓ DOWNLOAD PDF
• 09/08/2022

  ARECOR GRANTED EUROPEAN PATENTS PROTECTING PROPRIETARY FORMULATIONS OF HIGH CONCENTRATION HUMIRA® BIOSIMILAR

  ↓ DOWNLOAD PDF
• 04/07/2022

  ARECOR ANNOUNCES PRESENTATION AT EASD 2022 OF PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES

  ↓ DOWNLOAD PDF
• 16/06/2022

  ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH A TOP 5 GLOBAL PHARMACEUTICAL COMPANY

  ↓ DOWNLOAD PDF
• 18/05/2022

  ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE

  ↓ DOWNLOAD PDF
• 28/04/2022

  ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING

  ↓ DOWNLOAD PDF
• 12/04/2022

  ARECOR ANNOUNCES ORAL PRESENTATION AT ATTD 2022 OF PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING, INSULIN FOR DIABETES

  ↓ DOWNLOAD PDF
• 28/03/2022

  ARECOR WINS INNOVATION IN BUSINESS AND BUSINESS PERSON OF THE YEAR AWARDS AT THE CAMBRIDGESHIRELIVE BUSINESS AWARDS

  ↓ DOWNLOAD PDF
• 23/03/2022

  ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS

  ↓ DOWNLOAD PDF
• 20/01/2022

  ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP

  ↓ DOWNLOAD PDF